What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 3.3% in the pre-market session after Barclays upgraded the company t...
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability ...
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Check out the companies making headlines this week: SAIC (NASDAQ:SAIC): Government IT services provider Science Applications International Corporation (NASDA...
Check out the companies making headlines yesterday: Limbach (NASDAQ:LMB): Building systems company Limbach (NASDAQ:LMB) rose by 8.1% on Wednesday after the s...
What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 3% in the afternoon session after the company agreed to acquire the ...
Fortrea has been on fire lately. In the past six months alone, the company’s stock price has rocketed 77%, reaching $18.31 per share. This was partly due to ...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Fortrea (NASDAQ:FTRE) reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving com
Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 4.5% year ...
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results this Wednesday morning. Here’s what to look for. Fortrea beat an...
Fortrea trades at $17.93 and has moved in lockstep with the market. Its shares have returned 13.3% over the last six months while the S&P 500 has gained 11.4...
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
Check out the companies making headlines yesterday: Fortrea (NASDAQ:FTRE): Clinical research company Fortrea Holdings (NASDAQ:FTRE) rose by 4.6% on Wednesday...
What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 4.6% in the morning session after Barclays raised its price target o...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
